Clinical

Dataset Information

0

VIC Regimen Versus Bevacizumab Plus Chemotherapy as First-Line Treatment for BRAF V600E-Mutated Advanced Colorectal Cancer


ABSTRACT: In this study, we compared first-line VIC regimen with chemotherapy plus bevacizumab in Chinese patients with initially unresectable BRAF V600E-mutated mCRC. The principal goal was to evaluate the safety of VIC regimen, and to investigate the tumor response, the radical resectability, and the patient survival.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2748402 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2745961 | ecrin-mdr-crc
| 2387736 | ecrin-mdr-crc
2013-12-31 | E-GEOD-50678 | biostudies-arrayexpress
2021-10-20 | E-MTAB-11004 | biostudies-arrayexpress
2018-06-02 | GSE115234 | GEO
2024-06-22 | PXD050614 | Pride
2022-05-01 | GSE193610 | GEO
2022-11-08 | GSE211576 | GEO
2014-04-21 | E-GEOD-49430 | biostudies-arrayexpress
| 2288489 | ecrin-mdr-crc